IBS and the Microbiome: What Recent Research Tells Us
Irritable bowel syndrome is closely linked to your gut microbiota. Here's what the science is revealing in 2025.
Published on
Your gut is home to an ecosystem — and in IBS, it's thrown off balance
Irritable bowel syndrome (IBS) affects around 10 to 15% of the adult population worldwide. Bloating, abdominal pain, diarrhoea, constipation, or a fluctuation between the two: symptoms vary widely, can be debilitating, and have long been poorly understood. Today, research is increasingly pointing to one central player: the gut microbiota.
This vast ecosystem of bacteria, viruses, and fungi that colonises your colon is far from a passive bystander. In IBS, it is profoundly disrupted — and that disruption may well be driving a significant proportion of your symptoms.
Dysbiosis: when the bacterial balance breaks down
The term dysbiosis refers to an imbalance in the gut microbiota. In IBS, this imbalance is now well documented across a growing body of research.
A meta-analysis covering 16 studies and more than 1,200 participants found a significant increase in the Firmicutes/Bacteroidetes ratio in IBS patients, particularly in the IBS-D subtype (predominant diarrhoea). This ratio, frequently cited as a marker of dysbiosis, reflects a reduction in microbial diversity.
More specifically, studies consistently observe the following in people with IBS:
- Increased levels of Clostridium, Escherichia coli, and Enterococcus
- Decreased levels of Bacteroides, Lactobacillus, and Bifidobacterium
These so-called "friendly" bacteria (Lactobacillus, Bifidobacterium) play a key role in protecting the gut lining and regulating inflammation. Their decline is therefore far from trivial.
The key mechanism: the gut barrier under strain
Understanding why dysbiosis causes symptoms means understanding the role of short-chain fatty acids (SCFAs). These molecules — such as butyrate — are produced when gut bacteria ferment dietary fibre. They nourish the cells lining the gut wall and maintain the integrity of the intestinal barrier.
When the microbiota becomes depleted, SCFA production drops. The consequences include:
- The intestinal barrier becomes permeable (the well-known leaky gut)
- Bacterial fragments cross the gut wall and trigger low-grade inflammation
- This inflammation activates the local immune system, which sends pain signals to the brain
It is this pathway — dysbiosis → reduced SCFAs → compromised barrier → inflammation → symptoms — that now sits at the heart of IBS research.
What the most recent studies show
In 2025, a case-control study comparing 25 IBS patients with 110 healthy controls confirmed lower alpha diversity in the IBS group, with a notable reduction in Firmicutes (particularly Clostridia) and an increase in Bacteroidota. These findings, consistent with other research, reinforce the idea that the IBS microbiome has a distinctive signature — one that is detectable and potentially exploitable.
A further meta-analysis incorporating 23 studies and 1,340 participants (covering the period 2019–2025) demonstrates significant, reproducible differences in levels of Lactobacillus, Bifidobacterium, E. coli, and Enterococcus between IBS patients and healthy individuals.
On a larger scale, a study published in 2025 in Nature involving 35,000 participants marks a step change in our ability to analyse the human microbiome — paving the way for predictive microbial signatures of conditions such as IBS.
Approaches to modulating the microbiota
The encouraging news is that the microbiota can be modified. Several strategies are showing promising results.
Probiotics are currently the best-evidenced intervention in IBS. They act directly on the mechanism described above: boosting SCFA production, strengthening the gut barrier, and reducing inflammation. Studies show symptom improvement across all IBS subtypes.
A fibre-rich diet supports microbial diversity and stimulates SCFA production. Fermentable fibres feed beneficial bacteria — yet another reason to pay close attention to what you put on your plate.
Preliminary data also suggest that a predominantly plant-based diet is associated with fewer symptoms and shorter flare-ups compared with a conventional omnivorous diet.
For severe cases, exclusive enteral nutrition remains a medically recognised option during flare-ups, although it temporarily disrupts the composition of the microbiota.
Finally, innovative approaches are emerging: encapsulated faecal transplantation and postbiotics (metabolites derived from bacteria) offer the prospect of targeted restoration of the microbial ecosystem, with a more favourable risk profile.
Key takeaways
IBS is not "all in the mind" — nor is it purely mechanical. It is a condition in which the microbiota, gut barrier, immune system, and brain are in constant dialogue with one another.
Research is moving quickly. While microbiome-specific therapies accessible to all remain on the horizon, the most effective lever available today remains a balanced diet, rich in fibre and low in ultra-processed foods, combined where appropriate with probiotic supplementation discussed with a healthcare professional.
Your microbiota is sending you signals. Perhaps it's time to start listening.